Unique dual mechanism of action of eprosartan: effects on systolic blood pressure, pulse pressure, risk of stroke and cognitive decline

References

• American Heart Association. Heart Disease and Stroke Statistics–2004 Update. American Heart Association, Dallas, TX, USA (2003).
   Google Scholar
• Chobanian AV, Bakris GL, Black HR et al. The Seventh Report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA289, 2560–2572 (2003).
   PubMed Web of Science ®Google Scholar
• ESH–ESC Guidelines Committee 2003. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens.21, 1011–1053 (2003).
   PubMed Web of Science ®Google Scholar
• Schrader J, Lüders S, Kulschewski A et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Principal results of a prospective randomized controlled study (MOSES). Stroke36, 1218–1226 (2005).
   PubMed Web of Science ®Google Scholar
• Shlyakhto E. Observational Study on Cognitive function And systolic blood pressure Reduction (OSCAR): preliminary analysis of 6-month data from >10,000 patients. Curr. Med. Res. Opin. (2007) (In Press).
   PubMedGoogle Scholar
• De la Sierra A. Effects of eprosartan on target organ protection. Vasc. Health Risk Manag.1, 1–7 (2005).
   Google Scholar
• De la Sierra A, Ram V. The pharmacological profile of eprosartan – implications for cerebrovascular and cardiovascular risk reduction. Curr. Med. Res. Opin. (2007) (In press).
   PubMedGoogle Scholar
• Brooks DP, Ruffolo RR. Pharmacological mechanism of angiotensin II receptor antagonists: implications for the treatment of elevated systolic blood pressure. J. Hypertens.17(Suppl. 2), S27–S32 (1999).
   PubMedGoogle Scholar
• Reit E. Actions of angiotensin on the adrenal medulla and autonomic ganglia. Fed. Proc.31(4), 1338–1343 (1972).
   PubMedGoogle Scholar
• Wong PC, Hart SD, Zaspel AM et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J. Pharmacol. Exp. Ther.255(2), 584–592 (1990).
   PubMed Web of Science ®Google Scholar
• Wong PC, Hart SD, Duncia JV, Timmermans JB. Nonpeptide angiotensin II receptor antagonists. Studies with DuP 753 and EXP3174 in dogs. Eur. J. Pharmacol.202(3), 323–330 (1991).
   PubMed Web of Science ®Google Scholar
• Wong PC, Bernard R, Timmermans TB. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension19(6 Pt 2), 663–667 (1992).
   PubMed Web of Science ®Google Scholar
• Rupp H. Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines? J. Hypertens. (2007).
   Google Scholar
• Dendorfer A, Raasch W, Tempel K, Dominiak P. Interactions between the renin–angiotensin system (RAS) and the sympathetic system. Basic Res. Cardiol.93(Suppl 2), 24–29 (1998).
   PubMedGoogle Scholar
• Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR Jr. Inhibition of sympathetic outflow by the angiotensin II receptor antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blockade. Pharmacology.55(5), 244–251 (1997).
   PubMed Web of Science ®Google Scholar
• Robins GW, Scott LJ. Eprosartan. A review of its use in the management of hypertension. Drugs65, 2355–2377 (2005).
   PubMed Web of Science ®Google Scholar
• Schmidt B, Drexler H, Schieffer B. Therapeutic effects of angiotensin (AT1) receptor antagonists: potential contribution of mechanisms other than AT1 receptor blockade. Drugs4, 361–368 (2004).
   Google Scholar
• Brooks RR, Ohlstein EH, Ruffolo RR Jr. Pharmacology of eprosartan, an angiotensin II receptor antagonist: exploring hypotheses from clinical data. Am. Heart J. 138(3 Pt 2), 246–251 (1999).
   PubMedGoogle Scholar
• Hollenberg NK, Sica DA. Review of eprosartan: a new angiotensin II receptor antagonist. Pharmacotherapy19(5 Pt 2), 71S–72S (1999).
   Google Scholar
• Ilson B. Drug interaction studies with eprosartan, a novel angiotensin II receptor antagonist. Am. J. Hypertens.11(4 Pt 2), 108A (1998) (Abstract E051).
   Google Scholar
• Pinheiro H, Moura D, Albino-Teixeira A et al. A comparison of AT1 angiotensin II antagonists at pre- and postjunctional angiotensin II receptors of the rat tail artery. Naunyn. Schmiedebergs. Arch. Pharmacol.366, 537–542 (2002).
   PubMedGoogle Scholar
• Arosio E, De Marchi S, Prior M et al. Haemodynamic effects of eprosartan and valsartan in hypertensive patients during isometric and mental stress. J. Hypertens.23, 1923–1927 (2005).
   PubMed Web of Science ®Google Scholar
• Balt JC, Mathy MJ, Pfaffendorf M et al. Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan. J. Hypertens.19, 2241–2250 (2001).
   PubMed Web of Science ®Google Scholar
• Tenero D, Martin D, Ilson B et al. Pharmacokinetics of intravenously and orally administered eprosartan in healthy males: absolute bioavailability and effect of food. Biopharm. Drug Dispos.38, 351–356 (1998).
   Google Scholar
• Chapelski MC, Martin DE, Tenero DM et al. A dose proportionality study of eprosartan in healthy male volunteers. J. Clin. Pharmacol.38, 34–39 (1998).
   PubMedGoogle Scholar
• Martin DE, Tompson D, Boike SC et al. Lack of effect of eprosartan on the single dose pharmacokinetics of orally administered digoxin in healthy male volunteers. Br. J. Clin. Pharmacol.43, 661–664 (1997).
   PubMed Web of Science ®Google Scholar
• Kannel W. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging20, 277–286 (2003).
   PubMed Web of Science ®Google Scholar
• Vaccarino V, Berger AK, Abramson J et al. Pulse pressure and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. Am. J. Cardiol.88, 890–986 (2001).
   PubMedGoogle Scholar
• Gradman AH, Gray J, Maggiocomo F et al. Assessment of once-daily eprosartan, an angiotensin II antagonist, in patients with systemic hypertension. Clin. Ther.21, 442–453 (1999).
   PubMed Web of Science ®Google Scholar
• Hedner T, Himmelmann A, for the Eprosartan Multinational Study Group. The efficacy and tolerance of one or two daily doses of eprosartan in essential hypertension. J. Hypertens.17, 129–136 (1999).
   PubMed Web of Science ®Google Scholar
• Punzi HA, Punzi CF. Once-daily eprosartan mesylate in the treatment of elderly patients with isolated systolic hypertension: data from a 13-week double-blind, placebo-controlled, parallel, multicenter study. J. Hum. Hypertens.18, 655–661 (2004).
   PubMedGoogle Scholar
• Teitelbaum I, Chilvers M, Reiz RJS. The angiotensin receptor blocker eprosartan mesylate reduces pulse pressure in isolated systolic hypertension. Can. J. Cardiol.20(Suppl. C), 11C–16C (2004).
   Google Scholar
• Elliott WJ. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. Eprosartan Study Group. J. Hum. Hypertens.13, 413–417 (1999).
   PubMedGoogle Scholar
• Sega R. Efficacy and safety of eprosartan in severe hypertension. Blood Press.8, 114–121 (1999).
   PubMed Web of Science ®Google Scholar
• Ruilope L, Jäger B, Pritchard B. Eprosartan versus enalapril in elderly patients with hypertension: a double-blind, randomized trial. Blood Press.10, 223–229 (2001).
   PubMed Web of Science ®Google Scholar
• Argenziano L, Trimarco B. Effect of eprosartan and enalapril in the treatment of elderly hypertensive patients: subgroup analysis of a 26-week, double-blind, multicentre study. Eprosartan Multinational Study Group. Curr. Med. Res. Opin.15, 9–14 (1999).
   PubMed Web of Science ®Google Scholar
• Levine B. Eprosartan provides safe and effective long-term maintenance of blood pressure control in patients with mild to moderate essential hypertension. Curr. Med. Res. Opin.17, 8–17 (2001).
   PubMed Web of Science ®Google Scholar
• Aranda P, Aranda FJ, Fernandez E et al. Long-term, safety and effectiveness of eprosartan in mild-to-moderate essential hypertensive patients: EPROSYST study. J. Hypertens.1(Suppl. 4), 66 (2003) (Abstract P1.165).
   Google Scholar
• De la Sierra A, Munoz A, Arcos E et al. Effect of eprosartan on pulse pressure and blood pressure components in patients with isolated systolic hypertension Blood Press.13(Suppl. 2), 5–10 (2004).
   PubMed Web of Science ®Google Scholar
• De la Sierra A, Munoz A, Arcos E et al. The effect of treatment with eprosartan on pulse pressure: factors predicting response. Can. J. Cardiol.20(Suppl. C), 17C–22C (2004b).
   Google Scholar
• Robles NR, Martin-Agueda B, Lopez-Munoz F et al. Effectiveness and safety of eprosartan on pulse pressure for the treatment of hypertensive patients. Int. J. Clin. Pract.59, 478–484 (2005).
   PubMed Web of Science ®Google Scholar
• Franklin SS. Hypertension in older people: part 1. J. Clin. Hypertens. (Greenwich)8, 444–449 (2006).
   PubMedGoogle Scholar
• Dhakam Z, McEniery CM, Yasmin et al. Atenolol and eprosartan: differential effects on central blood pressure and aortic pulse wave velocity. Am. J. Hypertens.19, 214–219 (2006).
   PubMed Web of Science ®Google Scholar
• Hill CE, Hirst GD, Silverberg GD et al. Sympathetic innervation and excitability of arterioles originating from the rat middle cerebral artery. J. Physiol.371, 305–316 (1986).
   PubMed Web of Science ®Google Scholar
• Böhm S, Kubista H. Fine tuning of sympathetic transmitter release via ionotropic and metabotropic presynaptic receptors. Pharmacol. Rev.54, 43–99 (2002).
   PubMedGoogle Scholar
• Straus SE, Majumdar SR, McAlister FA. New evidence for stroke prevention. JAMA.288, 1388–1395 (2002).
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J et al. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N. Engl. J. Med.342, 145–153 (2000).
   PubMed Web of Science ®Google Scholar
• PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack. Lancet358, 1033–1041 (2001).
   PubMed Web of Science ®Google Scholar
• Jalowy A, Schulz R, Heusch G. AT1 receptor blockade in experimental myocardial ischemia/reperfusion. Basic Res. Cardiol.93(Suppl. 2), 85–91 (1998).
   PubMed Web of Science ®Google Scholar
• Fournier A, Achard JM, Boutitie F et al. Is the angiotensin II Type 2 receptor cerebroprotective? Curr. Hypertens. Rep.6, 182–189 (2004).
   PubMedGoogle Scholar
• Siragy HM, Carey RM. Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. Hypertension33(5), 1237–1242 (1999).
   PubMed Web of Science ®Google Scholar
• Thone-Reineke C, Steckelings UM, Unger T. Angiotensin receptor blockers and cerebral protection in stroke. J. Hypertens.25(Suppl.), S115–S121 (2006).
   Google Scholar
• Labiós M, Martínez M, Gabriel F et al. Effect of eprosartan on cytoplasmic free calcium mobilization, platelet activation, and microparticle formation in hypertension. Am. J. Hypertens.17, 757–763 (2004).
   PubMed Web of Science ®Google Scholar
• Martinez Silvestre M. The effects of eprosartan on cytoplasmic free calcium mobilization, platelet activation and microparticle formation in hypertension. Could they be relevant to stroke prevention? JRAAS.6(Suppl. 1), S1–S3 (2005).
   Google Scholar
• Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet363, 2022–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Dahlöf B, Devereux RB, Kjeldsen S et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet359, 995–1003 (2002).
   PubMed Web of Science ®Google Scholar
• Farmer ME, White LR, Abbott RD et al. Blood pressure and cognitive performance. The Framingham Study. Am. J. Epidemiol.126, 1103–1114 (1987).
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson K, Skoog I et al. The Study on COgnition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J. Hypertens.21, 875–886 (2003).
   PubMed Web of Science ®Google Scholar
• Elias MF, Wolf PA, D’Agostino RB et al. Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study.Am. J. Epidemiol.138, 353–364 (1993).
   PubMed Web of Science ®Google Scholar
• Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet.352, 1347–1351 (1998).
   PubMed Web of Science ®Google Scholar
• McGuinness BV, Todd S, Passmore P et al. Blood pressure lowering in patients without prior cerebrovascular disease for prevention of cognitive impairment and dementia. Cochrane Database Syst. Rev.2, CD004034 (2006).
   Google Scholar
• Pathak A, Hanon O, Negre-Pages L et al. Rationale, design and methods of the OSCAR study: observational study on cognitive function and systolic blood pressure reduction in hypertensive patients. Fundam. Clin. Pharmacol.21, 199–205 (2007).
   PubMedGoogle Scholar
• Rupp H, Jäger B. The renin–angiotensin system and the sympathetic nervous system in hypertension and congestive heart failure: implications for therapeutic interventions. J. Clin. Basic Cardiol.4, 47–51 (2001).
   Google Scholar